Guidance on Incorporating Anti-EGFR Therapy in 1L CRC Practice

Ibrahim Sahin

Anti-EGFR Therapy in CRC: How to Manage Toxicities

Ibrahim Sahin

CRC Highlights From ASCO® GI 2024: Dual IO Approaches

Fight Colorectal Cancer

V. Morris

2024 Updates on 1L MSI-H/dMMR mCRC and Using ctDNA MRD Testing in Ea…

Total Health

A. Grothey

Treating HER2-Amplified mCRC

Ibrahim Sahin

Colon Cancer Molecular Tumor Board: Elderly Patient With MSI-High Ma…

Total Health

A. Grothey

Colorectal Cancer: What's Current in Epidemiology, Risk Factors, and…

UNC Lineberger Comprehensive Cancer Center

L. Gangarosa

The Rising Tide of CRC in Younger Adults: Why Is This Happening & Wh…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

C. Eng

ASCO® 2024 Insights: "PanaMa Trial - FU/FA Maintenance Therapy With …

2024 ASCO® Annual Meeting Insights Hub

D. Modest

ESMO GI 2024 Insights: CodeBreaK 300 - Patient-Reported Tolerability…

Insights from 2024 ESMO GI Annual Meeting

J. Taieb

Integrating MMR/MSI, RAS, BRAF, and HER2 as Targetable Biomarkers In…

Marc Peeters

The Importance of 1L Biomarkers in CRC

Nicholas DeVito

ASCO® 2024 Summary: "CRC Key Studies Including TRANSMET, CheckMate 8…

2024 ASCO® Annual Meeting Insights Hub

R. Kim, T. Biachi

ASCO® 2024 Summary: "Expert Panel Discussion on CRC Including TRANSM…

2024 ASCO® Annual Meeting Insights Hub

N. Uboha, K. Spencer, M. Cecchini

EGFR Targeted Therapy for mCRC: Differences Between Cetuximab and Pa…

Benjamin Weinberg

Treating KRAS-Mutated mCRC

Ibrahim Sahin